Last checked at 6 Dec 2022 12:00
6 December 2022
ValiRx PLC ("ValiRx" or the "Company")
Shareholder Communications and Investor Webinar
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces an update regarding shareholder communications.
We are pleased to invite shareholders to join us for a Live Webinar Q&A on 13 December 2022 at 2pm where members of the Board will be available to answer questions. The webinar will be hosted via the BRR Media platform with registration details posted on our website closer to the event.
We would like to thank Dr Adam Hargreaves for acting in the role of Shareholder Representative over the past three months. This trial period to assess benefits to both the Company and to shareholders has now concluded and we have mutually agreed to discontinue the role going forwards.
ValiRx CEO, Dr Suzy Dilly commented "I look forward to meeting shareholders in our webinar and will endeavour to answer questions and concerns as fully as possible.
I would particularly like to extend my appreciation to Adam for the time and effort he has contributed over the past three months in the Shareholder Representative role. It has been a useful experience for us, however, the regulatory constraints and commercial sensitivity around sharing information led us to reconsider the value of this initiative and to concentrate on our previous shareholder communication channels."
*** ENDS ***
For more information, please contact:
ValiRx plc
Dr Suzanne Dilly, CEO
| Tel: +44 (0) 2476 796496 www.valirx.com Suzanne.Dilly@valirx.com
|
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive Sue Carr - Director
| +44 (0) 115 787 0206 www.vformation.biz
lucy@vformation.biz sue@vformation.biz |
Cenkos Securities plc (Joint Broker)
Russell Kerr/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate Finance) | Tel: +44 (0) 20 7397 8900 |
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker | Tel: +44 (0) 20 3657 0050
|
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.